Cantor Fitzgerald analyst Sarah James maintains $HCA Healthcare (HCA.US)$ with a buy rating, and adjusts the target price from $315 to $405.
According to TipRanks data, the analyst has a success rate of 60.1% and a total average return of 8.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $HCA Healthcare (HCA.US)$'s main analysts recently are as follows:
The firm projected some disruptions due to hurricanes but did not foresee the company's 2025 EBITDA and EPS projections falling below street expectations, which is a reversal from a previous period of consistent outperformance. Despite being intrigued by the recent 9% stock decline, the firm suggests that the shares may experience a phase of consolidation going forward.
HCA Healthcare's third-quarter performance managed to withstand the negative impacts of hurricanes, a trend that's anticipated to persist into the fourth quarter and possibly lead to a fiscal year 2024 guidance that aligns with the lower end of expectations. Despite the ongoing challenges posed by these natural disasters, the company's management is projecting earnings growth for 2025 to meet or exceed its long-term objectives, supported by an admissions growth prediction of 3%-4%, which is considered above the usual trend.
Investor expectations were high leading into the third quarter, yet HCA Healthcare's underlying performance remained robust, evidenced by same-store revenues climbing 7.1% despite a strong third-quarter comparison from the previous year at 7.9%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
坎托·菲茨杰拉德分析师Sarah James维持$HCA医疗 (HCA.US)$买入评级，并将目标价从315美元上调至405美元。
根据TipRanks数据显示，该分析师近一年总胜率为60.1%，总平均回报率为8.4%。
此外，综合报道，$HCA医疗 (HCA.US)$近期主要分析师观点如下：
该公司预计由于飓风造成了一些中断，但并未预见到2025年该公司EBITDA和每股收益预期低于市场预期，这与之前持续表现出色的时期形成了反转。尽管对最近的股价下跌9%感到好奇，但该公司表示股票可能会经历一段整固阶段。
hca医疗的第三季度表现顶住了飓风的负面影响，这一趋势预计将持续至第四季度，并有可能导致2024财年指引与预期下限保持一致。尽管这些自然灾害带来了持续的挑战，但公司管理层预计2025年的盈利增长将达到或超过其长期目标，支撑因员增长预测为3%-4%，这被认为高于通常的趋势。
投资者的期望在进入第三季度时很高，然而尽管与前一年相比第三季度的同店销售额仍然强劲增长7.1%，表明hca医疗的基础表现依然良好，而前一年的同期比较为7.9%。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
